Biotech Values

[poorgradstudent]

The real takeaway from the BMY-INHX filing, IMO, is that there are too many freaking investment bankers taking too large a cut of the pie.

Given:

- the recent shenanigans of the banking industry in general

and

- the intentionally suggestive yet ambiguous ways that companies (especially biotech) describe what they have in hand,


then what assurance does a bidder have that the banker is being completely truthful about the intent and degree of seriousness of competing bidders? This area seems ripe for a little bit of abuse.